217 related articles for article (PubMed ID: 18508790)
1. Aberrant expression of microRNA in polycythemia vera.
Bruchova H; Merkerova M; Prchal JT
Haematologica; 2008 Jul; 93(7):1009-16. PubMed ID: 18508790
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
4. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis.
Bruchova H; Yoon D; Agarwal AM; Mendell J; Prchal JT
Exp Hematol; 2007 Nov; 35(11):1657-67. PubMed ID: 17976518
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
[TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. Two clinical phenotypes in polycythemia vera.
Spivak JL; Considine M; Williams DM; Talbot CC; Rogers O; Moliterno AR; Jie C; Ochs MF
N Engl J Med; 2014 Aug; 371(9):808-17. PubMed ID: 25162887
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms.
Ha JS; Jung HR
Ann Clin Lab Sci; 2015; 45(3):308-14. PubMed ID: 26116595
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
10. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
11. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
13. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression profile in granulocytes from primary myelofibrosis patients.
Guglielmelli P; Tozzi L; Pancrazzi A; Bogani C; Antonioli E; Ponziani V; Poli G; Zini R; Ferrari S; Manfredini R; Bosi A; Vannucchi AM;
Exp Hematol; 2007 Nov; 35(11):1708-18. PubMed ID: 17976522
[TBL] [Abstract][Full Text] [Related]
16. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
18. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
19. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
20. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
